Alliance for Pandemic Preparedness

December 17, 2020

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19



Keywords (Tags): ,

  • An interim analysis of the ongoing randomized placebo-controlled phase 1-3 trial of the antibody cocktail REGN-COV2 among non-hospitalized patients with COVID-19 (n=228) found a larger reduction in SARS-CoV-2 viral load among patients in the treatment group vs. the placebo group, with a mean difference of -0.41 log10 copies per milliliter (95% CI, −0.71 to −0.10). Among those in the treatment group, patients who were serum antibody negative at baseline, had higher baseline viral loads, and who received a higher treatment dose (8g vs 2.4g) had larger mean differences in viral load compared to the placebo group.
  • The prespecified clinical endpoint was the proportion of participants with at least one COVID-19 medically attended visit (telehealth, medical office visit, urgent care, emergency department, or hospitalization) in 29 days of follow-up, which was 3% in the treatment group and 6% in the placebo group. Among those who were serum antibody-negative, 6% in the treatment group had a medically attended visit compared to 15% in the placebo group.

Weinreich et al. (Dec 17, 2020). REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. New England Journal of Medicine.